03:25 PM EST - Oncolytics Biotech Inc. : announced that it has completed patient enrollment in its U.S. Phase II clinical trial using intravenous administration of REOLYSIN in combination with gemcitabine (Gemzar®) in patients with advanced or metastatic pancreatic cancer (REO 017). Oncolytics Biotech Inc.
shares T.ONC are trading down $0.03 at $2.03.
